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GPR4 is a pH-sensingGprotein-coupled receptor highly expressed in vascular endothelial cells and can
be activated by protons in the inflamed tissue microenvironment. Herein, we report that acidosis-
inducedGPR4 activation increases paracellular gap formation and permeability of vascular endothelial
cells through the Ga12/13/Rho GTPase signaling pathway. Evaluation of GPR4 in the inflammatory
response using the acute hindlimb ischemia-reperfusion mouse model revealed that GPR4 mediates
tissue edema, inflammatory exudate formation, endothelial adhesion molecule expression, and leuko-
cyte infiltration in the inflamed tissue. Genetic knockout and pharmacologic inhibition of GPR4
alleviate tissue inflammation. These results suggest GPR4 is a pro-inflammatory receptor and could
be targeted for therapeutic intervention.
INTRODUCTION
The endothelium is a dynamic barrier that can mediate the transvascular movement of fluids and immune
cells between the peripheral blood and interstitial tissues. During active inflammation, the production of
numerous inflammatory mediators within the inflammatory loci can increase endothelial gap formation
and vascular permeability, which facilitate leukocyte infiltration and exudate formation in the inflamed tis-
sues (Edlow and Sheldon, 1971; Muller, 2003; Pate et al., 2010). Accumulating evidence suggests that
microenvironmental factors, such as acidic pH, can stimulate endothelial cell inflammation (Chen et al.,
2011; Dong et al., 2013, 2017b; Okajima, 2013; Tobo et al., 2015). Inflammatory tissues are characteristically
acidic, owing in part to hypoxia and increased glycolytic metabolism of cells and infiltrated leukocytes re-
sulting in heightened proton production and accumulation. The acidic tissue microenvironment is associ-
ated with a wide range of inflammation-related disease states such as arthritis, inflammatory bowel disease,
myocardial infarction, stroke, and limb ischemia. Previous reports note that local pH ranging from 6.0 to 7.0
is common in the microenvironments of inflamed tissues, solid tumors, and ischemic tissues (Huang and
McNamara, 2004; Justus et al., 2013; Lardner, 2001; Siesjo et al., 1996). In ischemic disease, one study
demonstrated that, within 50 min of coronary artery occlusion, local tissue extracellular pH decreased
from 7.4 to 5.5 in domestic pigs (Hirche et al., 1980). Furthermore, in the tourniquet-induced rabbit limb
ischemia model, local tissue pH decreased rapidly within 1 h and dropped from 7.30 to 6.36 during the
4-h course of limb ischemia (Hagberg, 1985). In summary, an acidic interstitial pH is an inflammatory micro-
environmental factor in many pathological conditions and has been demonstrated to modulate tissue,
blood vessel, and immune cell functions (Huang and McNamara, 2004; Justus et al., 2013; Lardner, 2001;
Siesjo et al., 1996).
Cells can sense extracellular acidification through multiple molecular sensors such as acid-sensing ion
channels (ASICs), transient receptor potential (TRP), and proton-sensing G protein-coupled receptors
(GPCRs) (Holzer, 2009; Justus et al., 2013; Okajima, 2013; Sanderlin et al., 2015). GPR4 is a member of
the proton-sensing GPCR family, which also includes GPR65 (TDAG8) and GPR68 (OGR1) (Justus et al.,
2013; Ludwig et al., 2003; Okajima, 2013; Sanderlin et al., 2015; Yang et al., 2007). GPR4 is highly expressed
in vascular endothelial cells (ECs) and has been shown to increase the expression of inflammatory cytokines,
chemokines, adhesion molecules, and ER stress-related genes upon activation by acidic pH in ECs (Chen
et al., 2011; Dong et al., 2013; Tobo et al., 2015). GPR4 has also been shown to potentiate inflammation
in vivo. Recent studies found that the genetic deletion of GPR4 in mouse colitis models decreased the
expression of endothelial adhesion molecules VCAM-1 and E-Selectin in the intestinal microvasculature,iScience 23, 100848, February 21, 2020 ª 2020 The Author(s).
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which was associated with reduced mucosal leukocyte infiltration and intestinal inflammation (Sanderlin
et al., 2017; Wang et al., 2018). Furthermore, GPR4 was shown to increase tissue injury in a renal
ischemia-reperfusion mouse model (Dong et al., 2017a).
Our current study focuses on the acidosis/GPR4-mediated endothelial paracellular gap formation and
vessel permeability in the inflammatory response. Using genetic and pharmacological approaches, we
demonstrate that activation of GPR4 by acidosis induces endothelial paracellular gap formation and
permeability through the Ga12/13 signaling pathway. Furthermore, we demonstrate that the genetic dele-
tion and pharmacological inhibition of GPR4 decrease blood vessel permeability, tissue edema, and leuko-
cyte infiltration in the acute hindlimb ischemia-reperfusionmousemodel. Our data suggest that GPR4 has a
proinflammatory role in the regulation of the inflammatory response.RESULTS
Acidosis Promotes Paracellular Gap Formation in Primary Endothelial Cells
Tissue acidosis commonly exists in inflammatory microenvironments (Dong et al., 2014b; Justus et al., 2013;
Lardner, 2001; Okajima, 2013; Sanderlin et al., 2015). However, the involvement of acidosis in endothelial
cell (EC) gap formation is largely unknown. Four primary vascular ECs were cultured to a confluent mono-
layer and were treated with either physiological pH 7.4 or acidic pH 6.4 for 5 h to assess acidosis-induced
paracellular gap formation. Under physiological pH 7.4, all ECs maintained a cellular monolayer with no
gap formation over the 5-h time course. However, under acidic pH 6.4 the cellular monolayers were disrup-
ted and paracellular gap formation was observed (Figure 1A). The gap formation of EC monolayers was
determined in human umbilical vein endothelial cells (HUVECs), human pulmonary artery ECs (HPAECs),
human colon microvascular ECs (HMVECs-Colon), and human lung microvascular ECs (HMVECs-Lung)
by calculating the total percent area of gaps in each field of view (Figures 1B–1E). ECs treated with acidic
pH 6.4 for 5 h developed approximately 4%–5% gap area relative to the total area (Figures 1B–1E). No gaps,
however, could be detected within physiological pH conditions.Acidosis Stimulates Endothelial Paracellular Gap Formation through the Proton-Sensing
GPR4 Receptor
To determine the role of the pH-sensing receptor GPR4 in acidosis-induced EC gap formation, we used
genetic and pharmacological approaches to modulate GPR4 expression and activity, respectively. HUVECs
were stably transduced with either control (HUVEC/vector), GPR4 overexpression (HUVEC/GPR4), or GPR4
signaling-defective mutant (HUVEC/GPR4 R115A) overexpression constructs. GPR4 knockdown was
achieved with transduction of GPR4 shRNA (HUVEC/GPR4 shRNA) and compared with control shRNA
(HUVEC/control shRNA). As previously described (Chen et al., 2011; Dong et al., 2013), real-time RT-PCR
analysis showed that GPR4mRNA expression was increased by14-fold in the overexpression HUVEC cells
and decreased by >90% in the shRNA knockdown cells (Figure S1). HUVECs were evaluated under physi-
ological pH 7.4 or acidic pH 6.4 for 5 h. Treatment with physiological pH 7.4 resulted in no observable gap
formation. However, under acidic pH 6.4, HUVEC/vector cell monolayers developed 4% gap formation
(Figure 2A). Overexpression of GPR4 significantly increased acidosis-induced gap formation by 2.5 fold
(10%–11%) under acidic conditions when compared with HUVEC/vector. Conversely, HUVEC/GPR4
R115A mutant decreased the percentage of gap area when compared with HUVEC/vector (1.8% versus
4%, respectively). Furthermore, knockdown of GPR4 by shRNA decreased the percentage of gap area
to 2.5% in acidic pH 6.4 conditions when compared with HUVEC/control shRNA (4.5%) (Figure 2B).
We next assessed the effects of a GPR4 inhibitor (EIDIP) on acidosis-induced paracellular gap formation in
HUVEC/vector and HUVEC/GPR4 cells (Figures 2C and 2D). Pharmacological inhibition of GPR4 attenuated
acidosis-induced gap formation. A dose-dependent decrease in the acidosis-induced gap development
could be observed with increasing inhibitor concentrations during HUVEC/vector and HUVEC/GPR4 treat-
ments when compared with vehicle (Figures 2C and 2D). The results indicate that acidosis-induced EC par-
acellular gap formation is dependent on GPR4 activation by acidic pH.GPR4-Mediated Ga12/13/Rho GTPase Signaling Is Involved in Endothelial Paracellular Gap
Formation in Response to Acidosis
Previous studies demonstrate that the Ga12/13/Rho GTPase pathway can regulate cytoskeletal dynamics,




Figure 1. Acidosis Stimulates Paracellular Gap Formation in Primary Vascular Endothelial Cells (ECs)
Plasma membrane staining and paracellular gap area quantitation of ECs treated for up to 5 h under physiological or
acidic pH. Acidosis increases EC gap formation when compared with physiological pH treatment conditions.
(A) Representative pictures of plasma membrane staining in human umbilical vein endothelial cells (HUVECs) at 0, 3, and
5 h treated under physiological or acidic pH.
(B–E) Quantitative analysis of gap formation in (B) HUVECs, (C) human pulmonary artery endothelial cells (HPAECs), (D)
human colon microvascular endothelial cells (HMVEC-Colon), and (E) human lung microvascular endothelial cells
(HMVEC-Lung) over 5 h. All experiments were performed in triplicate and are representative of four experiments. Data at
each time point are presented as meanG SEM and analyzed for statistical significance between the pH 7.4 group and the
pH 6.4 group using the unpaired t test where **p < 0.01 and ***p < 0.001. White arrows point to paracellular gaps. Scale
bar, 100 mm.2004). In line with these observations, GPR4 can couple to Ga12/13 and Rho GTPase when expressed in can-
cer cell lines (Castellone et al., 2011; Justus and Yang, 2015). For this reason, we investigated the role of the
GPR4/Ga12/13/Rho GTPase pathway in acidosis-induced EC gap formation. The p115 RGS Ga12/13 inhibi-
tory construct (Kozasa et al., 1998; Yang et al., 2005) was stably transduced into HUVEC/vector and HU-
VEC/GPR4 cells. We next performed the gap formation assay under physiological and acidic pH conditions
for 5 h. HUVEC/p115 RGS cells treated with acidic pH had significantly reduced gap formation when
compared with the vector control (Figures 3A and 3B). Furthermore, thiazovivin and staurosporine, two
chemical inhibitors for Ga12/13 downstream effectors Rho-associated kinase (ROCK) and myosin light-chain
kinase (MLCK), respectively (Justus and Yang, 2015), were used in HUVEC/vector and HUVEC/GPR4 cellsiScience 23, 100848, February 21, 2020 3
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Figure 2. Activation of GPR4 by Acidosis Induces Paracellular Gap Formation in HUVECs
(A–D) Quantitative analysis of gap formation utilizing genetic and pharmacological approaches to modulate GPR4 expression or activity. (A) HUVEC/vector,
HUVEC/GPR4, and HUVEC/R115A cells. (B) HUVEC/control shRNA and HUVEC/GPR4 shRNA cells. (C) HUVEC/vector and (D) HUVEC/GPR4 cells treated
with GPR4 inhibitor or vehicle. All cells were treated with physiological pH 7.4 or acidic pH 6.4 for 0, 1, 2, 3, 4, and 5 h and the percent of gap area was
quantified. DMSOwas used as vehicle control. All experiments were performed in duplicate or triplicate and are representative of three experiments. Data at
each time point are presented asmeanG SEM and analyzed for statistical significance using the ANOVAwhere *p < 0.05, **p < 0.01, and ***p < 0.001. Black,
blue, and red symbols indicate statistical analysis between groups indicated by bracket markers.under acidic conditions. Thiazovivin significantly decreased gap formation percentage in HUVEC/vector
and HUVEC/GPR4 cells when compared with the vehicle controls under acidic pH. Staurosporine nearly
abolished acidosis-induced gap formation in HUVEC/vector and HUVEC/GPR4 cells (Figures 3C and
3D). Collectively, the results suggest that acidosis-induced EC gap formation relies, at least in part, on
the GPR4/Ga12/13 pathway. Additionally, our results demonstrated that acidosis also induced F-actin stress
fiber formation and decreased VE-cadherin expression at the site of paracellular gaps in ECs (Figures S2
and S3). To assess the role of actin cytoskeleton in acidosis/GPR4-mediated EC gap formation, HUVECs
were treated with an actin cytoskeleton inhibitor cytochalasin D (CytoD). Cytochalasin D significantly
reduced acidosis-induced gap formation in HUVEC/vector and HUVEC/GPR4 cells (Figures 3C and 3D).
Moreover, p115 RGS, thiazovivin, staurosporine, and cytochalasin D substantially decreased F-actin stress
fiber formation in HUVECs (Figure S4). Taken together, these results suggest that the Ga12/13/Rho/ROCK/
MLCK/actin cytoskeleton pathway is important for acidosis/GPR4-induced endothelial paracellular gap
formation.
Acidosis Increases Endothelial Cell Permeability through GPR4
We next assessed if GPR4-dependent paracellular gap formation can functionally result in increased endo-
thelial permeability. Endothelial permeability was assessed by the fluorescein isothiocyanate conjugated-
dextran (FITC-dextran) permeability assay whereby diffusion of FITC-dextran through the endothelial
monolayer from the upper to lower chamber of the Transwell insert was assessed. Cells were treated
with physiological pH 7.4 or acidic pH 6.4 for 5 h followed by the addition of FITC-dextran. Acidic pH treat-
ment significantly increased FITC-dextran permeability in HUVEC/vector cells when compared with phys-
iological pH. Moreover, when GPR4 is overexpressed and treated with acidic pH there was a further in-
crease in acidosis-induced FITC-dextran when compared with HUVEC/vector cells. When GPR4
expression is knocked down or signaling is defective (R115A mutant) (Chen et al., 2011), FITC-dextran
permeability was significantly decreased compared with controls under acidic conditions (Figure 4). These
results suggest that acidosis increases EC permeability through GPR4.4 iScience 23, 100848, February 21, 2020
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Figure 3. The Ga12/13/Rho GTPase Pathway Is Involved in Acidosis/GPR4-Mediated Paracellular Gap Formation in HUVECs
(A–D) Quantitative analysis of GPR4/Ga12/13-mediated paracellular gap formation in HUVECs. GPR4-mediated paracellular gap formation is dependent, at
least in part, on the Ga12/13/Rho GTPase/ROCK/MLCK/actin cytoskeleton pathway in response to acidic pH. HUVECs were treated with various inhibitors,
including p115-RGS (an inhibitory construct of Ga12/13), thiazovivin (a Rho-associated kinase ROCK inhibitor), staurosporine (a myosin light-chain kinase
MLCK inhibitor), and cytochalasin D (an actin cytoskeleton inhibitor). The Ga12/13 p115-RGS inhibitory construct in (A) HUVEC/vector and (B) HUVEC/GPR4
cells. Pharmacological inhibition of the Ga12/13/Rho GTPase/ROCK/MLCK/actin cytoskeleton pathway using 5 mM thiazovivin (TA), 1.3 nM staurosporine
(STA), or 5 nM cytochalasin D (CytoD) in (C) HUVEC/vector or (D) HUVEC/GPR4 cells. HUVECs were treated with either physiological pH 7.4 or acidic pH 6.4
for up to 5 h. All experiments were performed in duplicate and are representative of at least three experiments. Data at each time point are presented as
mean G SEM and analyzed for statistical significance using ANOVA where *p < 0.05, **p < 0.01, and ***p < 0.001. Black, blue, and purple symbols indicate
statistical analysis between groups indicated by bracket markers.Genetic Deletion of GPR4 Reduces Tissue Edema and Inflammation in the Acute Hindlimb
Ischemia-Reperfusion Mouse Model
Next, we assessed the functional role of GPR4 in a tourniquet cuff-based acute hindlimb ischemia-reper-
fusion mouse model (Bonheur et al., 2004). This mouse model can cause severe inflammation resulting
in increased vessel permeability, tissue edema, and leukocyte infiltration in the affected tissue. The
ischemia-reperfusion associated inflammation was induced in wild-type (WT) and GPR4 knockout (KO)
mice. Consistent with previous report (Yang et al., 2007), the absence of GPR4 mRNA expression in KO
mouse tissues was confirmed by RT-PCR (Figure S5). The sham and cuff limbs were measured for circum-
ference differences between pre- and post-procedure measurements. GPR4 KO mice had less observable
tissue edema in the tourniquet-affected limb following the ischemia and reperfusion event when compared
with WT mice (Figure 5).
Inflammatory exudates in the interstitial space between the skin and the limb muscle/body peritoneum on
the tourniquet subjected side were collected and measured followed by histology (Figure 6). GPR4 KO
mice had reduced inflammatory exudate when compared with the WT mice (6 versus 65 mg, respec-
tively) (Figures 6A, 6B, and 6I). Furthermore, histological analysis of the inflammatory exudates revealed
that GPR4 KO mice had reduced leukocyte infiltrates when compared with WT (Figures 6D, 6F, and 6J).
No red blood cells were observed in the exudate, suggesting that the exudate is due to increased vascular
permeability but not vessel hemorrhaging (Figures 6A–6F). To further assess the GPR4-mediated vessel
permeability, we performed immunohistochemistry for plasma protein immunoglobulin G (IgG) and de-
tected IgG within inflammatory exudates (Figures 6G and 6H), indicating an increased vascular perme-
ability to plasma protein. Furthermore, less plasma IgG could be observed in the GPR4 KO cuff-affectediScience 23, 100848, February 21, 2020 5
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Figure 4. GPR4 Activation by Acidosis Increases Cellular Permeability in HUVECs
(A and B) Quantitative analysis of cellular permeability in vitro. GPR4 activation by acidic pH increases cellular
permeability using the FITC-dextran cellular permeability assay with HUVECs. Relative fold increase of cellular
permeability in (A) HUVEC/vector, HUVEC/GPR4, and HUVEC/R115A cells and (B) HUVEC/control shRNA and HUVEC/
GPR4 shRNA cells. Cells were treated for 5 h with either physiological pH 7.4 or acidic pH 6.4. All experiments were
performed in duplicate and are representative of at least three experiments. Data are presented as mean G SEM and
analyzed for statistical significance using ANOVA where *p < 0.05, **p < 0.01, and ***p < 0.001.tissues compared with WT cuff-affected tissues indicating reduced endothelial cell permeability in the KO
(Figures 6G and 6H). We also performed immunohistochemistry of CD31 (a pan-endothelial marker) to
assess blood vessel density in the hindlimb dermis and hypodermis tissues. No significant difference in
blood vessel density was observed between WT and GPR4 KO or between sham and cuff-affected dermis
and hypodermis tissues within the 24-h ischemia and reperfusion (Figure S6).
To provide a molecular explanation for GPR4-mediated inflammation within vascular endothelial cells, we
performed immunohistochemistry to examine the expression of VCAM-1 and E-selectin within the endo-
thelium of the cuff and sham-affected dermis and hypodermis tissues. Overall, VCAM-1 and E-selectin pro-
tein expression was increased within the cuff-affected limb vasculature when compared with sham (Fig-
ure 7). Immunohistochemical analysis of VCAM-1 revealed expression on a variety of cell types, such as
skeletal muscle, fibroblast, and vascular endothelial cells, which is consistent with the previous literature
(Epperly et al., 2002; Ulyanova et al., 2005). Interestingly, we observed a decrease of VCAM-1 proteinA B
Figure 5. GPR4 Deficiency Reduces Tissue Edema in the Inflammatory Hindlimb Ischemia-Reperfusion (IR) Mouse
Model
(A and B) Upper and lower leg circumferences in wild-type (WT, N = 7) and GPR4 knockout (GPR4 KO, N = 6) mice were
measured before and after IR. The change of leg circumference was calculated (value after IR – value before IR) and used
as an indicator for tissue edema. GPR4 deficiency reduces the change of upper and lower leg circumference when
compared with WT mice in the IR mouse model. Quantitative analysis of (A) upper and (B) lower leg circumference
changes. Data are presented as mean G SEM and analyzed for statistical significance using ANOVA where *p < 0.05,
**p < 0.01, and ***p < 0.001.
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Figure 6. GPR4 Deficiency Reduces Inflammatory Exudate Production and Leukocyte Infiltration in the Ischemic
Hindlimb Tissues
(A–J) Inflammatory exudate measurements and leukocyte infiltration quantification in WT and GPR4 KO mice following
the ischemia-reperfusion of the hindlimb. Genetic deletion of GPR4 reduces inflammatory exudate production and
leukocyte infiltration into the inflammatory exudate. Gross representative images of observable exudate formation in (A)
WT and (B) GPR4 KO mice in the interstitial space between the skin and muscle of the ischemic hindlimb. Representative
images of H&E staining of (C) WT sham, (D) WT cuff, (E) GPR4 KO sham, and (F) GPR4 KO cuff inflammatory exudate
sections. Black brackets indicate exudate distribution. Arrows indicate infiltrated leukocytes in the inflammatory exudate.
Red brackets indicate skin tissues. Representative images of mouse plasma IgG protein in (G) WT cuff and (H) GPR4 KO
cuff sections. IgG protein can be visualized as brown signal. The plasma protein IgG is used as a marker to indicate blood
vessel permeability. Quantitative analysis of (I) exudate weight and (J) leukocyte infiltration from multiple fields of view
(FOV). 10x and 20x microscope objectives used. Scale bar indicates 100 mm. Data analyzed from seven WT and six GPR4
KOmice. Data are presented as meanG SEM and analyzed for statistical significance using the unpaired two-tailed t test
where ***p < 0.001.expression on vascular endothelial cells in GPR4 KO cuff-affected dermis and hypodermis of the limbs
when compared with WT (Figures 7A–7D and 7I). E-selectin expression was observed on endothelial cells
and fibroblasts as previously reported (Bajnok et al., 2017; Harashima et al., 2001; Vainer et al., 1998). Similar
to VCAM-1 expression patterns, there is an observable decrease in endothelial E-selectin protein expres-
sion in GPR4 KO cuff-affected dermis and hypodermis of the limbs when compared withWT (Figures 7E–7H
and 7J).
Pharmacological Inhibition of GPR4 Reduces Tissue Edema, Leukocyte Infiltration, and
Vascular Permeability in the Hindlimb Ischemia-Reperfusion Mouse Model
To further assess the role of GPR4, we incorporated the use of a highly potent and selective GPR4 antag-
onist (referred to as GPR4 antagonist 13) (Velcicky et al., 2017) within the acute hindlimb ischemia-reperfu-
sion mouse model. Our results demonstrated that the GPR4 antagonist 13 significantly decreased upper
and lower limb tissue edema measured by the circumference of the leg compared with limbs of the vehicle
control (Figure 8). In addition, there was significantly less leukocyte infiltration within the inflammatory
exudate in the GPR4 antagonist 13-treated mice when compared with the vehicle-treated mice (Figures
9A, 9B, and 9F). Furthermore, the exudate weight was also decreased in GPR4 antagonist 13-treated
mice when compared with vehicle (Figure 9E). Additionally, vascular permeability was assessed and there
was a reduction in plasma IgG diffusion in the exudate by the treatment of the GPR4 antagonist 13 when
compared with vehicle treatment (Figures 9C and 9D). GPR4 antagonist 13 treatment also reduced the level
of an inflammatory marker, C-reactive protein (CRP), in themouse serum (Figure S7). To further examine the
role of GPR4 within ECs, we performed immunohistochemistry to analyze the expression of VCAM-1 and
E-selectin within the endothelium of the cuff-affected dermis and hypodermis tissues. We observed that
ECs in the GPR4 antagonist 13-treated mice had reduced VCAM-1 and E-selectin protein expression
compared with the vehicle-treated mice (Figure 10). Taken together, these data suggest that GPR4 can
mediate inflammation, vessel permeability, and leukocyte infiltration into inflamed tissues.
DISCUSSION
This study demonstrates that activation of GPR4 by acidic pH can stimulate endothelial inflammation
through the mediation of paracellular gap formation and permeability by the Ga12/13 pathway. We also
evaluate the functional role of GPR4 in the inflammatory response within the hindlimb ischemia-reperfusion
mouse model using GPR4-null mice and a selective GPR4 antagonist (Velcicky et al., 2017). These data sug-
gest that both the genetic knockout and pharmacological inhibition of GPR4 reduce the inflammatory
response in the ischemia-reperfusion mouse model. These results indicate GPR4 could be a valuable ther-
apeutic target for the remediation of inflammatory disease states.
The inflamed tissue microenvironment has been characterized by a loss of pH homeostasis. Acidosis is a
microenvironmental stress factor in which both stromal and infiltrated immune cells exist and that alters
cellular function (Lardner, 2001; Okajima, 2013; Sanderlin et al., 2015). Interestingly, local acidosis has
been described as a danger signal within ischemic and inflamed tissues that can promote inflammation (Ra-
jamaki et al., 2013). However, the way by which cells sense the altered acidic microenvironment and sub-
sequently alter the inflammatory response has only recently been investigated. Cells can employ distinct
acid-sensing mechanisms such as TRPs, ASICs, and proton-sensing GPCRs (Holzer, 2009; Okajima, 2013;
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Figure 7. Immunohistochemistry of VCAM-1 and E-Selectin Protein Expression in the Loose Connective Dermal
Tissue of WT and GPR4 KO Mice
(A–J) Immunohistochemical analysis of adhesion molecules VCAM-1 and E-selectin protein expression in vascular
endothelial cells within mouse dermal tissue sections of sham and cuff affected hindlimbs. GPR4-deficient mice had
reduced expression of VCAM-1 and E-selectin in vascular endothelial cells in cuff-affected tissues when compared with
WT. Representative pictures of VCAM-1 signal in (A) WT sham, (B) WT cuff, (C) GPR4 KO sham, and (D) GPR4 KO cuff
tissues. Representative pictures of E-selectin expression can be visualized in (E) WT sham, (F) WT cuff, (G) GPR4 KO sham,
and (H) GPR4 KO cuff tissues. Quantitative scoring analysis of (I) VCAM-1 and (J) E-selectin protein expression in vascular
endothelial cells in WT and GPR4 KO cuff-affected dermal tissues. Pictures taken with 63x objective. Scale bar indicates
100 mm. Arrows indicate blood vessels. Data are presented as mean G SEM and were analyzed for statistical significance
using the unpaired two-tailed t test where ***p < 0.001.the protonation of several histidine residues on the extracellular domains of the receptors, which can
induce conformational changes in the GPCRs for subsequent G protein activation and downstream
signaling (Liu et al., 2010; Ludwig et al., 2003). The family of proton-sensing GPCRs include GPR4,
GPR65 (TDAG8), and GPR68 (OGR1). GPR65 and GPR68 are predominately expressed in immune cells,
whereas GPR4 is expressed in endothelial cells (Dong et al., 2014b; Justus et al., 2013; Okajima, 2013; Sand-
erlin et al., 2015). This family of receptors has only recently been implicated in the regulation of post-
ischemic cellular responses and inflammation (Dong et al., 2014a; Ma et al., 2017; Matsuzaki et al., 2011;
Russell et al., 2012; Sanderlin et al., 2015).
For example, GPR68 has been suggested to have a cardioprotective function by establishing a cellular pro-
tective border zone around the infarcted tissues (Russell et al., 2012). GPR65 expression was increased in rat
brains and inhibited neuronal apoptosis and post-ischemic inflammatory responses following the middle
cerebral artery occlusion and reperfusion event (Ma et al., 2017). Studies investigating the role of GPR4 un-
der ischemic conditions are predominately focused on the kidney (Dong et al., 2014a). A recent study
demonstrated that GPR4 deficiency improved renal ischemia-reperfusion injury clinical parameters such
as survival rate, serum creatinine, and blood urea nitrogen levels. Furthermore, genetic deficiency of
GPR4 deterred apoptosis by suppressing CHOP expression in the kidney (Dong et al., 2017a). This study
is consistent with our previous report demonstrating CHOP expression is dependent on GPR4 activation
in HUVECs (Dong et al., 2013, 2017b). However, these previous studies did not investigate the role of
GPR4 in post-ischemic vessel permeability or inflammation.
Our current study reveals a functional role for GPR4 in governing endothelial paracellular gap formation
and permeability in response to acidic stress through the Ga12/13 pathway. Using both genetic and phar-
macological approaches, we demonstrated that acidosis-induced GPR4 activation significantly increases
the paracellular gap formation and permeability when compared with physiological pH in vitro. The
acidosis/GPR4-induced HUVEC paracellular gap formation is mediated through the Ga12/13/Rho
GTPase/ROCK/actin cytoskeleton pathway. It has been previously reported that activation of GPR4 by
acidosis can stimulate several downstream G protein pathways including G12/13, Gs, and Gq (Liu et al.,
2010; Ludwig et al., 2003). Future study is needed to elucidate the role of the complex signaling pathways
of GPR4 in paracellular gap formation and other biological processes. Several potential mechanisms
should be considered such as biased GPCR signaling and one G protein signaling pathway interacting
with/overpowering another G protein signaling pathway. Other potential mechanisms, such as G pro-
tein-independent pathways and indirect effects due to cytokine/chemokine generation, should also be
considered. Furthermore, a previous study reported that GPR4 can reduce endothelial cell barrier function
via lysophosphatidylcholine (LPC) (Qiao et al., 2006). However, the LPC-GPR4 ligand binding interaction
was unable to be confirmed (Zhu et al., 2001). Instead, GPR4 has been shown to function as a pH sensor
(Ludwig et al., 2003; Yang et al., 2007). Altered endothelial cell permeability can lead to detrimental com-
plications, such as tissue edema. Many diseases related to ischemia-induced inflammation are associated
with increased vascular permeability such as stroke, myocardial infarction, sepsis, and cancer (Kumar et al.,
2009). Our study suggests that GPR4 mediates endothelial paracellular gap formation and permeability in
response to acidotic stress within the acidic inflamed microenvironment. For this reason, we further inves-
tigated the functional role of GPR4 in mediating acute inflammation using the hindlimb ischemia-reperfu-
sion mouse model.
To investigate GPR4 in the ischemia-reperfusion model, we used the GPR4 KO mice for comparison with
WT mice. Our data demonstrated that GPR4 KO mice had reduced parameters of acute inflammation10 iScience 23, 100848, February 21, 2020
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Figure 8. Pharmacological Inhibition of GPR4 Reduces Tissue Edema in the Inflammatory Hindlimb Ischemia-
Reperfusion (IR) Mouse Model
(A and B) Upper and lower leg circumference changes following IR in wild-type (WT) mice treated with either vehicle or
GPR4 antagonist 13. GPR4 antagonist 13 reduces the changes of upper and lower leg circumference when compared with
vehicle control in the IR mouse model. Quantitative analysis of (A) upper and (B) lower leg circumference changes,
respectively. N = 10 vehicle- and N = 10 GPR4 antagonist 13-treated mice. Data are presented as mean G SEM and were
analyzed for statistical significance using the ANOVA where *p < 0.05, **p < 0.01, and ***p < 0.001.such as tissue edema, inflammatory exudate formation, leukocyte infiltration, and EC adhesion molecule
expression (VCAM-1 and E-selectin). These results suggest GPR4 mediates ischemia/reperfusion-induced
inflammation most likely through vascular inflammatory programs such as increased vessel permeability
and adhesion molecule expression. We and others have previously demonstrated that GPR4 regulates
endothelial cell inflammation and ER stress responses (Chen et al., 2011; Dong et al., 2013, 2017b; Tobo
et al., 2015). Activation of GPR4 in human endothelial cells by acidic pH increased numerous inflammatory
cytokines, chemokines, cellular adhesionmolecules, and ER stress-related genes (Dong et al., 2013, 2017b).
Additionally, activation of GPR4 in HUVECs functionally mediated EC-leukocyte interactions, which are
necessary for the leukocyte extravasation process in the inflammatory response (Chen et al., 2011; Dong
et al., 2013). The role of GPR4 in the regulation of inflammation has recently been evaluated in vivo using
the dextran sulfate sodium (DSS)-induced colitis mouse model (Sanderlin et al., 2017; Wang et al., 2018).
GPR4 KO mice were protected from intestinal inflammation and had reduced adhesion molecule expres-
sion in intestinal microvascular endothelial cells when compared with WT mice (Sanderlin et al., 2017).
These data suggest GPR4 potentiates inflammation likely through increased vascular endothelial cell in-
flammatory responses and are consistent with observations made in this current study and implicate
GPR4 as a potential therapeutic target for the remediation of acute and chronic inflammation. It should
also be noted that the GPR4 KO mice used in this study and other previous studies are global knockout
with GPR4 deficiency in all tissue types (Dong et al., 2017a; Ludwig et al., 2003; Sanderlin et al., 2017;
Wang et al., 2018; Yang et al., 2007). Although GPR4 is predominantly expressed in vascular endothelial
cells, global knockout of GPR4 in other cell types might also have biological effects. Future research to
generate endothelium-specific knockout mice will help further define the role of GPR4 in inflammatory re-
sponses and vascular biology.
Previous reports have indicated a group of imidazopyridine derivatives, found to selectively inhibit GPR4,
can reduce both endothelial cell inflammation in vitro and tissue inflammation in vivo (Dong et al., 2013,
2017b; Fukuda et al., 2016; Miltz et al., 2017; Tobo et al., 2015). We previously demonstrated that GPR4 in-
hibitors can inhibit GPR4 activation in HUVECs following acidotic stimulation in vitro, which resulted in
reduced expression of GPR4-mediated proinflammatory cytokines, chemokines, and cellular adhesion
molecules (Dong et al., 2017b). Previous in vivo studies evaluated GPR4 inhibitors in myocardial infarction,
arthritis, nociception, and angiogenesis mouse models and demonstrated that GPR4 inhibition reduced
the disease severity when compared with vehicle control (Fukuda et al., 2016; Miltz et al., 2017). Recently,
GPR4 antagonist 13, a pyrazolopyrimidine derivative was developed by Novartis Pharmaceuticals as the
next generation of GPR4 inhibitors and found to be more selective for GPR4 inhibition and orally active
(Velcicky et al., 2017). GPR4 antagonist 13 was also tested against other pH-sensing GPCRs, the H3iScience 23, 100848, February 21, 2020 11
Figure 9. GPR4 Antagonist 13 Reduces Inflammatory Exudate Production and Leukocyte Infiltration in the
Ischemic Hindlimb Tissues
(A–F) Inflammatory exudate measurements and leukocyte infiltration quantification in WT mice provided with vehicle or
GPR4 antagonist 13 in the hindlimb ischemia-reperfusion mouse model. GPR4 antagonist 13 reduces inflammatory
exudate formation and leukocyte infiltration in the exudate. Representative images of H&E staining of (A) WT vehicle cuff
and (B) WT GPR4 antagonist 13 cuff skin tissue sections. Immunohistochemical staining of mouse plasma IgG protein in
(C) WT vehicle cuff and (D) WT GPR4 antagonist 13 cuff inflammatory exudate sections. IgG protein can be visualized as
brown signal. (E) Total exudate formation and (F) leukocyte infiltration frommultiple fields of view (FOVs) when compared
with vehicle control following ischemia-reperfusion. Black brackets indicate exudate distribution. Arrows indicate
infiltrated leukocytes. 10x and 20x microscope objectives used. Scale bars indicate 100 mm. Data analyzed from 10 vehicle-
and 10 GPR4 inhibitor-treated mice. Data are presented as mean G SEM and were analyzed for statistical significance
using the unpaired two-tailed t test or ANOVA where **p < 0.01 and ***p < 0.001.receptor, and hERG channel and demonstrated high selectivity for GPR4. The in vivo pharmacokinetics
were also evaluated for GPR4 antagonist 13 and found to have good profiles of oral delivery and clearance.
GPR4 antagonist 13 was found to effectively reduce arthritic inflammation, hyperalgesia, angiogenesis, and
colitis (Sanderlin et al., 2019; Velcicky et al., 2017).
We sought to evaluate the anti-inflammatory effects of GPR4 antagonist 13 within the hindlimb ischemia-
reperfusion mouse model. Notably, we observed similar effects of the pharmacological inhibition of GPR4
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Figure 10. Immunohistochemistry of VCAM-1 and E-Selectin Protein Expression in the Loose Connective Dermal
Tissue of Wild-Type Mice Treated with GPR4 Antagonist 13 or Vehicle
(A–J) Immunohistochemical analysis of adhesion molecules VCAM-1 and E-selectin protein expression in vascular
endothelial cells within mouse dermal tissue sections of sham and cuff-affected hindlimbs. WT mice treated with GPR4
antagonist 13 had reduced expression of VCAM-1 and E-selectin in vascular endothelial cells in cuff-affected tissues when
compared with vehicle control. Representative pictures of VCAM-1 signal in (A) WT vehicle sham, (B) WT vehicle cuff, (C)
WT GPR4 antagonist 13 sham, and (D) WT GPR4 antagonist 13 cuff dermal connective tissues. Representative pictures of
E-selectin expression can be visualized in (E) WT vehicle sham, (F) WT vehicle cuff, (G) WT GPR4 antagonist 13 sham, and
(H) WT GPR4 antagonist 13 cuff dermal tissues. Quantitative scoring analysis of (I) VCAM-1 and (J) E-selectin protein
expression in vascular endothelial cells in WT vehicle and WT GPR4 antagonist 13 cuff-affected dermal tissues. Pictures
taken with 63x microscope objective. Scale bar indicates 100 mm. Arrows indicate blood vessels. Data are presented as
mean G SEM and were analyzed for statistical significance using the unpaired two-tailed t test where ***p < 0.001.that GPR4 exacerbated post-ischemia/reperfusion tissue inflammation. GPR4 antagonist 13 administration
resulted in a decrease in gross edema clinical parameters, inflammatory exudate formation, and leukocyte
infiltration. Moreover, GPR4 antagonist 13 treatment reduced endothelial permeability as evidenced by a
decrease in plasma IgG protein leakiness when compared with vehicle control. Proinflammatory modula-
tors such as endothelial adhesion molecules (VCAM-1 and E-selectin) were also decreased by GPR4 antag-
onist 13 compared with vehicle.
Taken together, this study demonstrates that GPR4 activation by acidosis can induce endothelial paracel-
lular gap formation and permeability in vitro. Furthermore, evaluation of the contribution of GPR4 in the
hindlimb post-ischemia/reperfusion inflammatory response supports the role for GPR4 in vascular perme-
ability and inflammation. Genetic knockout and pharmacological inhibition of GPR4 in vivo can decrease
leukocyte infiltration and the expression of endothelial adhesion molecules VCAM-1 and E-selectin and
can reduce vascular permeability as evidenced by attenuated plasma IgG leakiness into the subcutaneous
connective tissues and exudate formation. The results suggest that inhibition of GPR4 can be exploited as a
potential approach to alleviate inflammation and tissue edema.
Limitations of the Study
This study focuses on the role of the proton-sensing receptor GPR4 in acidosis-mediated endothelial para-
cellular gap formation, permeability, and inflammatory response. In addition to the proton-sensing GPCRs,
there are other types of acid sensors such as ASICs and TRPs (Holzer, 2009; Okajima, 2013; Sanderlin et al.,
2015; Wemmie et al., 2006). It remains to be determined whether there are functional interactions between
the proton-sensing GPCRs and other acid sensors in endothelial cell biology. Additionally, although this
study and other preclinical studies demonstrate that the GPR4 antagonists exhibit anti-inflammatory, anti-
nociceptive, and tissue-protective effects (Dong et al., 2013, 2017b; Fukuda et al., 2016; Miltz et al., 2017;
Sanderlin et al., 2019; Tobo et al., 2015; Velcicky et al., 2017), the potential therapeutic effects of GPR4 an-
tagonists in human patients remain to be evaluated.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2020.100848.
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Figure S1. Expression of GPR4 mRNA in HUVECs. Related to Figure 2. (A and B) Real-time RT-
PCR was performed to assess the expression of GPR4 mRNA in HUVEC/Vector, HUVEC/GPR4,
HUVEC/Control shRNA and HUVEC/GPR4 shRNA cells. GPR4 was overexpressed ~14 fold in the
HUVEC/GPR4 cells and knocked down >90% in the HUVEC/GPR4 shRNA cells when compared
to the control HUVEC cells (A and B, respectively). Each cDNA sample was run in duplicate for
the real-time RT-PCR analysis, and the 18S rRNA was used as the internal control for data




Figure S2. GPR4 activation by acidic pH induces actin stress fiber formation in HUVECs.
Related to Figure 3. (A-D) Actin stress fiber formation in HUVECs treated with physiological
or acidic pH. Activation of GPR4 by acidic pH 6.4 increases actin stress fibers when
compared to physiological pH 7.4 in HUVECs. Representative images of F-actin labeled with
rhodamine phalloidin in (A) HUVEC/vector pH 7.4, (B) HUVEC/vector pH 6.4, (C)
HUVEC/GPR4 pH 7.4, and (D) HUVEC/GPR4 pH 6.4. HUVECs were treated with pH




Figure S3. VE-Cadherin protein expression is reduced on endothelial paracellular gap borders.
Related to Figure 3. (A-D) VE-Cadherin protein expression in HUVECs treated with physiological
or acidic pH. Acidosis/GPR4-mediated endothelial paracellular gap areas have reduced VE-
Cadherin expression along endothelial cell borders. Representative images of VE-Cadherin
expression in (A) HUVEC/vector pH 7.4, (B) HUVEC/vector pH 6.4, (C) HUVEC/GPR4 pH 7.4, and
(D) HUVEC/GPR4 pH 6.4. HUVECs were treated with pH stimulation medium for 5 hours. Scale








Figure S4. Inhibition of the Gα12/13/Rho GTPase/ROCK/MLCK/actin cytoskeleton pathway decreases
acidosis/GPR4-induced actin stress fiber formation in HUVECs. Related to Figure 3. (A-J) Actin stress fiber
formation in HUVEC/GPR4 cells treated with various inhibitors, including p115-RGS (an inhibitory construct of
Gα12/13), thiazovivin (a Rho-associated kinase ROCK inhibitor), staurosporine (a myosin light chain kinase MLCK
inhibitor), and cytochalasin D (an actin cytoskeleton inhibitor). Representative images of F-actin labeled with
rhodamine phalloidin in (A) HUVEC/GPR4/pQCXIP vector pH 7.4, (B) HUVEC/GPR4/pQCXIP vector pH 6.4, (C)
HUVEC/GPR4/p115-RGS pH 7.4, (D) HUVEC/GPR4/p115-RGS pH 6.4, (E) HUVEC/GPR4 pH 7.4, (F)
HUVEC/GPR4 pH 6.4, (G) HUVEC/GPR4 pH 6.4 DMSO, (H) HUVEC/GPR4 pH 6.4 thiazovivin, (I) HUVEC/GPR4
pH 6.4 staurosporine, and (J) HUVEC/GPR4 pH 6.4 cytochalasin D. HUVECs were treated with pH stimulation


































































Figure S5. Absence of GPR4 mRNA expression in the GPR4 knockout mouse tissues. Related
to Figures 5, 6 and 7. (A) RT-PCR and (B) real-time RT-PCR were performed to assess the
expression of GPR4 mRNA in wild-type (WT) and GPR4 knockout (KO) mouse tissues. GPR4
mRNA expression was detected in the WT mouse heart, lung, and skin tissues but was absent
in the GPR4 KO mouse tissues. Each cDNA sample was run in duplicate for the real-time RT-PCR
analysis, and the 18S rRNA was used as the internal control for data normalization. The 2-ΔCt








































Figure S6. Blood vessel density in WT and GPR4 KO mouse hindlimb dermal tissues. Related to Figure 6.
(A-E) Blood vessels were delineated by immunohistochemistry (IHC) with a pan-endothelial cell marker CD31
in the sham or cuff-affected mouse hindlimb dermal tissues. (A) WT sham, (B) WT cuff, (C) GPR4 KO sham,
(D) GPR4 KO cuff, and (E) blood vessel density per field of view (FOV). No significant difference in blood
vessel density was observed between WT and GPR4 KO or between sham and cuff affected dermal tissues.
Arrows indicate blood vessels. 20x microscope objectives used. Scale bars indicate 100µm. Data are
presented as mean± SEM and was analyzed for statistical significance using the ANOVA. ns: not significant.






















Figure S7. Mice treated with GPR4 antagonist 13 have
reduced serum C-reactive protein levels when compared to
vehicle control. Related to Figure 9. C-reactive protein (CRP)
inflammatory marker in mouse serum. As previous indicators
suggest GPR4 antagonist 13 reduces inflammation in the
hindlimb ischemia-reperfusion mouse model, we assessed the
anti-inflammatory effects of GPR4 antagonist 13 in the
reduction of CRP levels in mouse serum. Mouse serum CRP
was measured by ELISA and represented as ng/mL. Data
analyzed from 10 WT/vehicle and 10 WT/GPR4 antagonist 13
mice. Data are presented as mean ± SEM and analyzed for




Chemicals and reagents.  For endothelial cell monolayer verification and live-cell staining, 
CellMask Deep Red Plasma Membrane Stain (#C10046) and NucBlue Live ReadyProbes Reagent 
(#R37605) were purchased from ThermoFisher Scientific (Waltham, MA, USA).  The monoclonal 
antibody for VE-Cadherin (D87F2) was purchased from Cell Signaling Technology (Danvers, 
MA, USA). Secondary antibody, Rhodamine Red-X goat anti-rabbit (ThermoFisher Scientific) 
was used for all immunofluorescence experiments. Cellular permeabilization agent Triton X-100 
detergent was purchased from BioRad (Hercules, CA, USA). Rhodamine Phalloidin used for F-
actin florescence staining was purchased from Cytoskeleton (Denver, CO, USA). For 
immunofluorescence staining, we used Vectashield Antifade Mounting Medium with DAPI from 
Vector Laboratories (Burlingame, CA, USA). To evaluate in vitro endothelial cell permeability, 
fluorescein isothiocyanate (FITC)-dextran (average molecular weight 10,000 Daltons) was 
purchased from Millipore Sigma (St. Louis, MO, USA). The chemicals used for buffering the pH 
stimulation media include 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), N-(2-
hydroxyethyl)-piperazine-N′-3-propanesulfonic acid (EPPS), 2-(4-morpholino)-ethanesulfonic 
acid (MES) and were purchased from Sigma-Aldrich (St Louis, MO, USA).  
The GPR4 inhibitor, 2-Ethyl-3-(4-(E-3-(4-isopropyl-piperazin-1-yl)-propenyl)-benzyl)-
5,7-dimethyl-3H-imidazo(4,5-b)pyridine (abbreviated as EIDIP), was purchased from Dalton 
Pharma Services (Toronto, ON, Canada) as previously described (Dong et al., 2017; Dong et al., 
2013). The new generation of GPR4 inhibitor, 2-(4-((2-Ethyl-5,7-dimethylpyrazolo[1,5-
a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole (GPR4 antagonist 13, also 
known as  NE-52-QQ57), was provided by Novartis Pharmaceuticals (Basel, Switzerland). The 
vehicle for GPR4 antagonist 13 was a combination of 0.5% methylcellulose purchased from 
BioConcept AG (Allschwil, Switzerland) and 0.5% Tween-80 purchased from Sigma-Aldrich (St. 
Louis, MO, USA) and 99% water.  
 
Cell culture.  Primary human umbilical vein endothelial cells (HUVEC), human pulmonary artery 
endothelial cells (HPAEC), and human lung microvascular endothelial cells (HMVEC-Lung) 
(Lonza, Walkersville, MD, USA), and primary human colon microvascular endothelial cells 
(HMVEC-Colon) (Cell Biologics Inc., Chicago, IL, USA) were cultured at 37°C and 5% CO2 in a 
humidified incubator for experimentation. HUVEC and HPAEC were cultured in endothelial cell 
growth medium 2 (EGM-2), while HMVEC-Lung and HMVEC-Colon were grown in EGM-2-
MV medium (Lonza, Walkersville, MD, USA).  
HUVECs stably expressing MSCV-IRES-GFP (HUVEC/Vector), MSCV-huGPR4-IRES-
GFP (HUVEC/GPR4), MSCV-huGPR4 R115A-IRES-GFP (HUVEC/GPR4-R115A), Flink-
control shRNA (HUVEC/Control shRNA), or Flink-huGPR4 shRNA (HUVEC/GPR4 shRNA) 
were developed by retroviral transduction and sorted by fluorescence-activated cell sorting 
(FACS) as previously described (Chen et al., 2011; Dong et al., 2017; Dong et al., 2013). To 
generate Gα12/13 signaling deficient HUVECs, the p115 RGS construct was cloned into the 
pQCXIP vector as previously described (Kozasa et al., 1998; Yang et al., 2005). The p115 RGS-
pQCXIP and empty pQCXIP retroviral vectors were stably transduced into the HUVEC/vector 
and HUVEC/GPR4 cells which were selected with 2µg/mL puromycin for 48 hours. Cells were 
used within 8 passages for all experiments. 
 
Gap formation assay.  Endothelial cells were seeded at 1x105 cells/well in a 24-well tissue culture 
treated plate and were cultured to a confluent monolayer. Intact cellular monolayers were 
confirmed using a deep red cellular membrane dye (ThermoFisher, #C10046, Waltham, MA, 
USA) and a live cell nuclear dye (ThermoFisher, #R37605, Waltham, MA, USA). Endothelial 
cells were then treated with cell culture medium buffered to physiological pH 7.4 or acidic pH 6.4 
for defined time points as previously described (Chen et al., 2011; Dong et al., 2017; Dong et al., 
2013). For assessment of pharmacological inhibition of GPR4 in vitro, the GPR4 inhibitor (EIDIP, 
Dalton Pharma) was added to the pH stimulation media following the GPR4 inhibitor pretreatment 
for 1 hour in physiological pH 7.4 (Dong et al., 2017; Dong et al., 2013). Pictures of endothelial 
cell monolayers were obtained hourly over a 5-hour period using the EVOS Digital Inverted 
Microscope imaging system. ImageJ software (NIH) was used to quantify gap percentage per field 
of view (FOV).  
 
Fluorescent filamentous-actin stress fiber formation assessment.  Following the gap formation 
assay, endothelial cells were washed with DPBS and fixed with 4% paraformaldehyde for 15 
minutes. Cells were then permeabilized for 10 minutes with 0.1% Triton X-100 and stained with 
Rhodamine Phalloidin for 30 minutes (Cytoskeleton Inc., Denver, CO, USA). Cells were then 
washed in DPBS and mounted with DAPI-containing Vectashield mounting media (Vector 
Laboratories, H-1200, Burlingame, CA, USA). Cells were imaged using the EVOS Digital 
Inverted Microscope imaging system. 
 
Immunofluorescence.  The endothelial cell monolayers in 24-well plates were treated with 
physiological pH 7.4 or acidic pH 6.4 media for 5 hours. Following pH treatments, cells were fixed 
with 4% paraformaldehyde for 15 minutes, permeabilized with 0.1% Triton X-100 for 5 minutes 
and blocked with goat serum in phosphate buffered saline with 0.1% Tween-20 for 1 hour. The 
cells were then incubated with VE-cadherin primary antibody (Cell Signaling Technology, D87F2) 
in the blocking solution overnight at 4°C. Cells were washed and incubated for 1 hour with 
Rhodamine Red-X goat anti-rabbit secondary antibody. The wells were then washed five times 
with PBS and mounted with a glass cover slip using Vectashield with DAPI. The stained cells 
were viewed and pictures taken with an EVOS Digital Inverted Microscope. 
 
Cellular permeability assay.  Endothelial cell monolayers were cultured to confluency on a 
Transwell membrane insert with 0.4µm pores (Corning, NY, USA) within a 24-well plate and 
subsequently treated with physiological pH 7.4 or acidic pH 6.4 media for 5 hours. Following pH 
treatment, fluorescein isothiocyanate (FITC)-dextran with average molecular weight of 10,000 
daltons (Millipore Sigma, St. Louis, MO, USA) diluted into pH stimulation medium was added 
into the upper chamber of the Transwell insert at a concentration of 1mg/mL. Subsequently, 1 mL 
of endothelial growth medium was also added to the lower chamber and the Transwell was 
incubated for 30 minutes at 5% CO2 at 37°C.  Following the incubation, 100µL of medium was 
drawn from the lower chamber and the FITC-dextran signal was quantified with a microplate 
reader at excitation/emission wavelength of 490/520 nm. The degree of cell permeability was 
determined by comparing the FITC-dextran fluorescent signal from the treatment group to the 
control group.  
 
Tourniquet-based acute hindlimb ischemia and reperfusion murine model.  All animal 
experiments were performed on 9-13-week old male and female mice. GPR4 wild-type (WT) or 
GPR4-deficient (GPR4 KO) mice backcrossed into the C57BL/6 genetic background for 11 
generations were used (Yang et al., 2007). To assess the inflammatory response post ischemia-
reperfusion, the mouse hindlimb ischemia reperfusion injury model was employed using the 
pneumatic digital tourniquet cuff system (Model DC1.6, Hokanson, Inc., Bellevue, WA, USA). 
Prior to tourniquet application, a single dose of 0.03 mg/kg Buprenorphine analgesics was 
administered subcutaneously to each mouse. Mice were then anesthetized with 1% isoflurane 
inhalation and placed on a temperature-controlled pad followed by the tourniquet application to 
the left proximal hindlimb under 200 mm Hg regulated pressure for 3hrs as previously described 
(Bonheur et al., 2004). During the tourniquet-induced hindlimb ischemia procedure, the mouse 
breathing rate and body temperature was monitored. Mice were injected subcutaneously with 0.5 
mL warm saline at the 1.5 hour and 3 hour time points for maintenance of hydration. After the 
tourniquet was released, the mice were placed into the microisolation cages with soft bedding for 
a 21 hour hindlimb reperfusion. Hindlimb circumference was measured before the procedure 
(baseline) and after the ischemia-reperfusion (IR), and the change in hindlimb circumference 
(value after IR – value at baseline) was used as an indicator to assess tissue edema. For the 
evaluation of GPR4 antagonist 13 (also known as NE-52-QQ57, Novartis) in the ischemia-
reperfusion mouse model, both C57BL/6J and GPR4 WT mice were used for experiments ranging 
from 9 to 13 weeks old. Mice were administered vehicle control (0.5% methylcellulose/ 0.5% 
Tween 80/ 99% water) or GPR4 antagonist 13 at 30 mg/kg b.i.d. by oral gavage one day prior to 
experimental procedure. Mice were given a second dose of vehicle or GPR4 antagonist 13 
approximately 2 hours prior to tourniquet cuff procedure. The last dose of either vehicle or GPR4 
antagonist 13 was administered 6 hours into the reperfusion phase. The dosage of 30 mg/kg b.i.d. 
was chosen because of the best efficacy observed in a previous study (Velcicky et al., 2017). All 
animal experiments were approved by the Institutional Animal Care & Use Committee of East 
Carolina University and were in accordance with the Guide for the Care and Use of Laboratory 
Animals administered by the Office of Laboratory Animal Welfare, NIH.  
 
Tissue collection and histological analysis.  After the 24 hour hindlimb ischemia-reperfusion 
procedure, mice were euthanized and the lower body was dissected for tissue collection. Upon 
dissection, inflammatory exudate within the interstitial space between upper leg muscle fibrous 
sheath and skin from the tourniquet-affected hindlimb was weighed and collected. A portion of 
the hindlimb skin containing inflammatory exudate was removed approximately 20 x 6 mm and 
fixed in 10% buffered formalin for tissue processing. The remaining exudate on the skin of the 
mouse was dissected and weighed. Tissues were embedded in paraffin, sectioned at 7µm, and 
stained with hematoxylin and eosin (H&E) for histopathological analyses. For assessment of 
neutrophilic infiltration into inflammatory exudate, pictures were taken from H&E tissue sections 
at five random points with a 20x objective. Leukocytes with the distinct polymorphic nuclear 
morphology were counted in each field of view (FOV) using ImageJ software in a blind manner 
as previously described (Sanderlin et al., 2017). Pictures were taken using the Zeiss Axio Imager 
A1 microscope.   
 
Immunohistochemistry.  Immunohistochemistry (IHC) was performed on serial sections of 7µm 
paraffin embedded skin with inflammatory exudate. Tissues were deparaffinized and hydrated to 
water by a series of declining ethanol concentrations. Antigen retrieval was performed using Tris-
EDTA (pH 9.0) with 0.1% Tween 20 to assess protein expression using the SuperPicture 3rd Gen 
Immunohistochemistry detection system (Invitrogen, Waltham, MA). Endogenous peroxidases 
were quenched and endogenous mouse IgG in blood serum was blocked using the Mouse-on-
Mouse blocking reagent (Vector Laboratories, Burlingame, CA). Subsequently, 10% normal goat 
serum was used to block tissue followed by primary antibody incubation with anti-VCAM-1 
(Abcam, ab134047), E-selectin (Abcam, ab18981, Cambridge, MA), and CD31 (Cell Signaling 
Technology, #77699, Danvers, MA) overnight at 4 °C and followed by incubation with secondary 
antibody. For detection, the Rabbit Vectastain Elite ABC-HRP Kit (Vector Laboratories, 
Burlingame, CA, USA) was employed according to the manufacture’s protocol. After IHC was 
performed, pictures were taken using a Zeiss Axio Imager A1 microscope. VCAM-1 and E-
selectin intensity in vascular endothelial cells were assessed using the scoring criteria as previously 
described: 1 = none/minimal, 2 = mild, 3 = moderate, 4 = high signal intensity (Sanderlin et al., 
2019). To quantify blood vessel density, CD31-positive blood vessels per field of view (FOV) was 
counted.   
To assess mouse plasma IgG protein in the exudate, the mouse Vectastain Elite ABC-HRP 
Kit was used (Vector Laboratories, Burlingame, CA). Endogenous peroxidase was quenched, 
blocking serum and biotinylated anti-mouse IgG secondary antibody was used followed by 
ImmPACT DAB Peroxidase Substrate (Vector Laboratories, Burlingame, CA) to visualize IgG 
leakiness from plasma. Immunohistochemical staining of tissue sections with no anti-mouse IgG 
antibody and the use of anti-Rabbit IgG antibody (Vector Laboratories, Burlingame, CA) were 
used for negative control. Pictures were taken with a Zeiss Axio Imager A1 microscope.  
 
Enzyme-linked immunosorbent assay (ELISA).  ELISA was performed to measure the C-
reactive protein (CRP) level in the serum of mice treated with the GPR4 antagonist 13 or vehicle 
control. Immediately after the mice were euthanized, blood was collected through cardiac puncture 
and allowed to form clots. After centrifugation, mouse serum on top of the clots was collected and 
stored in a -80 oC freezer for further analysis. The CRP concentration in mouse serum was 
measured using the mouse CRP ELISA kit (Sigma-Aldrich, RAB1121) according to the 
manufacturer’s protocol. 
 
RNA isolation and real-time RT-PCR.  Total RNA was isolated from HUVECs and mouse 
tissues using the DNA/RNA/Protein extraction kit (IBI Scientific, Peosta, IA) and reverse 
transcribed into cDNA using the SuperScript IV reverse transcriptase (ThermoFisher Scientific, 
Waltham, MA). Real-time PCR was performed in duplicate with a program of 50°C for 2 min, 
95°C for 10 min followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. Data was acquired 
using the QuantStudio 3 Real-Time PCR system (ThermoFisher Scientific, Waltham, MA) and 
analyzed using the 2-ΔCt method. TaqMan primer-probe sets used for gene expression analysis 
include 18S rRNA (Hs99999901_s1), mouse Gpr4 (Mm00558777_s1), and human GPR4 (custom 
designed) as previously described (Chen et al., 2011; Dong et al., 2013). Additionally, regular RT-
PCR was performed to assess mouse Gpr4 expression in WT and GPR4 KO mouse tissues as 
previously described (Yang et al., 2007). The mouse Gpr4 primer sequences for regular RT-PCR 
were: (sense) 5’-CAAGACCCACTTGGACCACA-3’ and (antisense) 5’-
TGTCCTGGGCCTCCTTTCTA-3’.  
 
Statistical Analysis.  GraphPad Prism software was used for statistical analysis. The results were 
recorded as the mean ± standard error from at least three independent experiments. For three or 
more groups, ANOVA was used followed by Bonferroni post hoc test. Statistical analyses between 
two groups were performed using the t-test. P < 0.05 was considered statistically significant.  
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